Safety, activity, and immune correlates of anti-PD-1 antibody in cancer (Q24633070)

13 November 2016

title

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

1 reference

30

Mario Sznol

0 references

Charles G. Drake

15

Charles G Drake

0 references

F Stephen Hodi

2

F Stephen Hodi

0 references

Tracee L. McMiller

21

Tracee L McMiller

0 references

Suzanne L. Topalian

1

Suzanne L Topalian

0 references

Drew M Pardoll

16

Drew M Pardoll

0 references

Janis M Taube

20

Janis M Taube

0 references

author name string

Julie R Brahmer

3

0 references

Scott N Gettinger

4

0 references

David C Smith

5

0 references

David F McDermott

6

0 references

John D Powderly

7

0 references

Richard D Carvajal

8

0 references

Jeffrey A Sosman

9

0 references

Michael B Atkins

10

0 references

Philip D Leming

11

0 references

David R Spigel

12

0 references

Scott J Antonia

13

0 references

Leora Horn

14

0 references

Lieping Chen

17

0 references

William H Sharfman

18

0 references

Robert A Anders

19

0 references

Haiying Xu

22

0 references

Alan J Korman

23

0 references

Maria Jure-Kunkel

24

0 references

Shruti Agrawal

25

0 references

Daniel McDonald

26

0 references

Georgia D Kollia

27

0 references

Ashok Gupta

28

0 references

Jon M Wigginton

The New England Journal of Medicine

29

0 references

language of work or name

English

0 references

publication date

28 June 2012

0 references

published in

0 references

volume

366

0 references

issue

26

0 references

page(s)

2443-54

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

The consensus coding sequences of human breast and colorectal cancers

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Enhancement of antitumor immunity by CTLA-4 blockade

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Cancer immunotherapy comes of age

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Toxicity and response criteria of the Eastern Cooperative Oncology Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Cancer immunotherapy comes of age

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Mechanisms of immune evasion by tumors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Optimizing therapy in previously treated non-small cell lung cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Do we need a different set of response assessment criteria for tumor immunotherapy?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Second-line treatment of advanced non-small cell lung cancer

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3544539

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22658127

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22658127